Polyphron

Polyphron is a pre-clinical stage biotechnology company dedicated to transforming the delivery of biologic medicines. Based in Oxford, UK, the company is developing a proprietary platform that enables the oral administration of proteins and peptides, which currently require injection. Their technology uses specialized polymer-based nanoparticles to shield therapeutics from gastric degradation and promote absorption in the small intestine. By focusing on high-impact areas such as metabolic disease, Polyphron aims to provide oral alternatives for treatments like insulin and GLP-1 receptor agonists. The company is a spin-out from the University of Oxford and is supported by leading life science investors.